Outlook Therapeutics to Present at Two Upcoming Investor Conferences
09/08/2020 - 08:05 AM
MONMOUTH JUNCTION, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics, will present at two upcoming investor conferences in September.
The following are the details for the conferences.
H.C. Wainwright 22nd Annual Global Investment Conference
Event: Fireside Chat Discussion and Q&A Date and Time: Monday, September 14, 2020 at 4:30 PM EDT Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Event: Fireside Chat Discussion and Q&A Date and Time: Monday, September 21, 2020 at 2:30 PM EDT In addition to the presentations, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend either of the conferences.
A live video webcast of the presentations will be accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com , approximately two hours after each event and will be archived for 90 days following the event.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com . CONTACTS: Media Inquiries: Jessica Morris Account Executive LaVoie Health Science T: 857.701.9731 jmorris@lavoiehealthscience.com
Investor Inquiries: Jenene Thomas Chief Executive Officer JTC Team, LLC T: 833.475.8247 OTLK@jtcir.com
OTLK Rankings
#4841 Ranked by Stock Gains
OTLK Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
United States
City
Iselin
About OTLK
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t